[Cost effectiveness of screening procedures for early detection of prostatic carcinoma: an overview].
OBJECTIVE
The authors attempted to provide an overview of current concepts and the status of research in the field of cost effectiveness analysis (CEA) of screening for prostate cancer (PCA).


METHODS
Basic concepts and methods of CEA were reviewed. Examples of CEA-related studies of PCA were obtained from pertinent literature through medical databases.


RESULTS
Screening for PCA has so far been restricted to limited groups of health care recipients, usually within the framework of clinical trials. In those trials, screening for PCA usually results in higher numbers of PCAs being detected at lower average stages in a given population. As a consequence of screening, the rate of potentially curable PCAs increases. However, it has not yet been demonstrated that screening for PCA decreases PCA-related mortality or morbidity from metastatic PCA. On the other hand, additional costs are associated with the screening measure and with increased use of resources for diagnosis and treatment of the additional PCAs detected through screening.


CONCLUSIONS
Throughout the European Union and North America, mass screening for PCA has not been implemented. This may chiefly be due to the current lack of information on long term benefits of PCA screening, particularly disease-specific survival. Currently, major studies are underway to assess the effects of PCA screening and its cost effectiveness. These studies include the US-American prostate, lung, colon and ovary trials (PLCO) and the European randomised study of Screening for Prostate Cancer (ERSPC).
Mueller-Lisse
U G
UG
Institut für Klinische Radiologie, Klinikum der Ludwig-Maximilians-Universität, Marchioninistr. 15, 81377 München. m-lisse@ikra.med.uni-muenchen.de
Mueller-Lisse
U L
UL
D014408:Biomarkers, Tumor / Q000097:blood; D003362:Cost-Benefit Analysis; D005060:Europe; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics*; D009656:North America; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000191:economics* / Q000401:mortality / Q000517:prevention & control; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen